Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Cambrex Expands Analytical Capabilities at Its High Point, NC Site

By Cambrex Corporation | December 11, 2018

Cambrex Corporation, a manufacturer of generic active pharmaceutical ingredients (APIs) and finished dosage forms, is investing another $1 million at its High Point, NC site to fit out 1,300 square feet of analytical laboratory space.

At the facility, Cambrex produces complex APIs and intermediates requiring multi-step synthetic processes in batch sizes from milligrams to 100kg to support clinical trials from Phase I to Phase III.

The expansion and fit out will include the installation of an additional 10 ultra-performance liquid chromatography instruments, the addition of nine chemical research and development scientists, and six analytical research and development scientists. 

The investment follows the new $3.2 million, 11,000-square-foot analytical laboratory, completed in April.

The site is licensed with the U.S. Drug Enforcement Administration (DEA) to manufacture Schedule II to Schedule V controlled substances. The acquisition enhanced Cambrex’s portfolio of small molecule API services and complements its large scale, multi-purpose manufacturing facilities in the U.S. and Europe.

This latest expansion at the 35,000-square-foot facility brings the investment at the site to more than $9 million since the acquisition of PhamaCore by Cambrex in 2016. It is set to be completed by year-end, according to the company.

(Source: Cambrex Corporation)

Related Articles Read More >

Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040
Cambridge Pharma launches with UK plant in Cambridge Research Park
Entegris logo
Entegris opens Life Sciences Technology Center in Massachusetts
sustainability
How pharma can optimize for right-the-first-time drug manufacturing and sustainability

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards